These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 8220403)

  • 21. A method for the evaluation of individual bioequivalence.
    Endrenyi L
    Int J Clin Pharmacol Ther; 1994 Sep; 32(9):497-508. PubMed ID: 7820334
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Update on the statistical analysis of bioequivalence studies.
    Steinijans VW; Hauschke D
    Int J Clin Pharmacol Ther Toxicol; 1992; 30 Suppl 1():S45-50. PubMed ID: 1601531
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sample size determination: extended tables for the multiplicative model and bioequivalence ranges of 0.9 to 1.11 and 0.7 to 1.43.
    Diletti E; Hauschke D; Steinijans VW
    Int J Clin Pharmacol Ther Toxicol; 1992 Aug; 30(8):287-90. PubMed ID: 1526691
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A distribution-free procedure for the statistical analysis of bioequivalence studies.
    Hauschke D; Steinijans VW; Diletti E
    Int J Clin Pharmacol Ther Toxicol; 1990 Feb; 28(2):72-8. PubMed ID: 2307548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A simple numerical approach towards improving the two one-sided test for average bioequivalence.
    Cao L; Mathew T
    Biom J; 2008 Apr; 50(2):205-11. PubMed ID: 18383447
    [TBL] [Abstract][Full Text] [Related]  

  • 26. On assessing bioequivalence using genomic data with model misspecification.
    Lu Q; Tse SK; Chow SC; Yang J
    J Biopharm Stat; 2009 Jul; 19(4):571-9. PubMed ID: 20183426
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sample size considerations for assessing individual bioequivalence based on the method of tolerance intervals.
    Esinhart JD; Chinchilli VM
    Int J Clin Pharmacol Ther; 1994 Jan; 32(1):26-32. PubMed ID: 8199749
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Symmetrical confidence intervals for bioequivalence trials.
    Westlake WJ
    Biometrics; 1976 Dec; 32(4):741-4. PubMed ID: 1009222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of bioequivalence using a multiplicative model.
    Chow SC; Peace KE; Shao J
    J Biopharm Stat; 1991; 1(2):193-203. PubMed ID: 1844696
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Update on the statistical analysis of bioequivalence studies.
    Steinijans VW; Hauschke D
    Int J Clin Pharmacol Ther Toxicol; 1990 Mar; 28(3):105-10. PubMed ID: 2318545
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A parametric confidence interval for a moment-based scaled criterion for individual bioequivalence.
    Kimanani EK; Potvin D
    J Pharmacokinet Biopharm; 1997 Oct; 25(5):595-614. PubMed ID: 9679224
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sample size calculation for the Power Model for dose proportionality studies.
    Sethuraman VS; Leonov S; Squassante L; Mitchell TR; Hale MD
    Pharm Stat; 2007; 6(1):35-41. PubMed ID: 17323313
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alternative confidence intervals for the assessment of bioequivalence in four-period cross-over designs.
    Quiroz J; Ting N; Wei GC; Burdick RK
    Stat Med; 2002 Jul; 21(13):1825-47. PubMed ID: 12111892
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessing bioequivalence using genomic data.
    Chow SC; Shao J; Li L
    J Biopharm Stat; 2004 Nov; 14(4):869-80. PubMed ID: 15587969
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparison of moment-based and probability-based criteria for assessment of follow-on biologics.
    Chow SC; Hsieh TC; Chi E; Yang J
    J Biopharm Stat; 2010 Jan; 20(1):31-45. PubMed ID: 20077247
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: a randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers.
    Parrillo-Campiglia S; Ercoli MC; Umpierrez O; Rodríguez P; Márquez S; Guarneri C; Estevez-Parrillo FT; Laurenz M; Estevez-Carrizo FE
    Clin Ther; 2009 Oct; 31(10):2224-32. PubMed ID: 19922893
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Bioequivalence and generic drugs. I. Studies of bioequivalence, considering the theoretical basis, design and use].
    Zapater P; Horga JF
    Rev Neurol; 1999 Dec 16-31; 29(12):1235-46. PubMed ID: 10652753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A small sample confidence interval approach to assess individual bioequivalence.
    Hyslop T; Hsuan F; Holder DJ
    Stat Med; 2000 Oct; 19(20):2885-97. PubMed ID: 11033583
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of Bayesian methods for multivariate bioequivalence measures.
    Molina de Souza R; Achcar JA; Martinez EZ
    J Biopharm Stat; 2009; 19(1):42-66. PubMed ID: 19127466
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A limited sampling approach in bioequivalence studies: application to long half-life drugs and replicate design studies.
    Mahmood I; Mahayni H
    Int J Clin Pharmacol Ther; 1999 Jun; 37(6):275-81. PubMed ID: 10395118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.